Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Medeor's series of product candidates each comprise a unique composition of different types of hematopoietic organ donor-derived cells, based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient, to achieve donor-specific immune tolerance, to prevent transplant organ loss, to reduce or eliminate chronic immunosuppressive drug therapy, and thereby to improve patient outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/27/17 | $57,000,000 | Series B |
6 Dimensions Capital RA Capital Management  Sofinnova Ventures Vivo Capital WuXi Healthcare Ventures | undisclosed |
